Zydus Cadila has received the final approval from the USFDA to market Tizanidine Tablets USP in the strengths of 2 mg and 4 mg.

The drug is used to treat muscle spasms caused by certain conditions such as multiple sclerosis, spinal cord injury and works by helping to relax the muscles.

It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.

The group now has more than 180 approvals and has so far filed over 320 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 11.3, or 2.94%, to trade at  Rs 395.10.  The total volume of shares traded  was  24,840 at the BSE (10.47 a.m., Tuesday).